Skip to main content

Alnylam Starts Phase I Study of siRNA Liver Cancer Drug


Alnylam Pharmaceuticals announced last week that it has initiated a phase I study of its siRNA-based liver cancer therapy ALN-VSP.

The study, the company said, will enroll an estimated 55 patients with advanced liver cancers, including hepatocellular carcinoma and other solid tumors with liver involvement, who are refractory to the standard of care.

The study is designed to evaluate the intravenous drug's safety, tolerability, pharmacokinetics, and pharmacodynamics.

"Other exploratory objectives include the assessment of tumor response through Response Evaluation Criteria for Solid Tumors, a set of published guidelines that define when cancer patients' disease improves, stabilizes, or progresses during treatment; change in tumor blood flow or vascular permeability measured by DCE-MRI; and change in plasma biomarkers of angiogenesis," Alnylam said.

"In addition, the analysis of pharmacodynamic effects of ALN-VSP on tumors will be measured in patients electing to proceed with voluntary pre- and post-treatment biopsies," the company added.

ALN-VSP, formerly ALN-VSP01, comprises two siRNAs: one targeting vascular endothelial growth factor, which is associated with angiogenesis, and the other targeting kinesin spindle protein, which has been linked to cell proliferation in various cancers. It is also formulated in a lipid nanoparticle developed by Alnylam partner Tekmira Pharmaceuticals.

Earlier this year, Alnylam released preclinical data showing that the drug inhibited tumor growth as measured by serum levels of alpha-fetoprotein. It was also found to significantly improve median survival in treated animals versus controls, and boost survival in treated animals compared with ones receiving the approved liver cancer treatment Nexavar (see RNAi News, 2/19/2009).

The preclinical data also suggested that combining ALN-VSP with Nexavar provided an even greater increase in survival benefit, Alnylam said at the time.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.